Nasdaq · Healthcare
SUTRO BIOPHARMA, INC. (STRO)
As-reported financials and recent SEC filings for SUTRO BIOPHARMA, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$102.5M
Net income
$-191.1M
Net margin
—
Diluted EPS
$-22.49
ROE
144.3%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M |
| Gross profit | — | — | — | — | — |
| Operating income | $-158.4M | $-238.5M | $-89.3M | $-128.9M | $-98.5M |
| Net income | $-191.1M | $-227.5M | $-106.8M | $-119.2M | $-105.5M |
| Diluted EPS | $-22.49 | $-29.40 | $-14.24 | $-18.80 | $-18.32 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →Largest Healthcare peers
Go deeper on STRO
Search SUTRO BIOPHARMA, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.